Novartis reports positive 144-week data for Scemblix in CML trial
Go back to Novartis reports positive 144-week data for Scemblix in CML trial| NOVARTIS AG (NYSE: NVS) | Delayed: 152.67 +3.74 (2.51%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $148.93 | 52 Week High | $89.15 | |||
| Open | $151.94 | 52 Week Low | $69.84 | |||
| Day High | $152.74 | P/E | N/A | |||
| Day Low | $151.36 | EPS | $0.00 | |||
| Volume | 738,169 | |||||
